This just in: Bayer is reportedly talking with potential buyers of its blood glucose meters business.
Naturally, no one is commenting on the record. But Reuters reports the story, based on "two people familiar with the matter." (Guess away as to who they are.) According to those sources, the German drugmaker has apparently held talks with companies interested in buying its diabetes care unit. That division isn't small potatoes, either, as it generates about $1.3 billion in annual sales.
Bayer, for its part, wants to grow in other areas and the diabetes division doesn't offer the all-important "synergies" with its other divisions, according to the story. That means a device firm seeking to boost its presence in the diabetes sector, a growing business if there ever was one, has everything to gain. More coming soon, no doubt.
- read the Reuters story